Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HominAb

Financiado

Cerrado

Discovering novel antibodies derived from the human body itself to treat neurode...

Discovering novel antibodies derived from the human body itself to treat neurodegenerative diseases Neurodegenerative diseases are one of the disease fields with the highest unmet need. Decades of research have been invested in finding cures, however almost none have been successful. Antibodies have great therapeutic potential t... ver más

31/05/2020

Mabylon AG

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MABYLON AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Mabylon AG

50.00K€ | Lider

Proyectos interesantes

NeuroQure

Medical Technol...

Biotechnology

150K€ Cerrado

PLEC2022-009400

Medical Technol...

Biotechnology

256K€ Cerrado

PDC2021-121051-I00

Medical Technol...

Immunology

138K€ Cerrado

CPP2021-008532

Medical Technol...

Biomedical Rese...

623K€ Cerrado

PredicTOOL

Medical Technol...

Nanotechnology

1M€ Cerrado

NeurAntigen

Medical Technol...

Biomedical Imag...

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2019-11-13
Fecha Fin: 2020-05-31

Líder del proyecto

MABYLON AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurodegenerative diseases are one of the disease fields with the highest unmet need. Decades of research have been invested in finding cures, however almost none have been successful. Antibodies have great therapeutic potential to treat these diseases as they are broadly applicable to specifically target different aspects of disease-causing processes. However, most of current non-human antibodies are limited by side-effects and a lack of specificity. Human-derived antibodies, derived from human blood samples, provide a solution for these limitations. They are naturally designed by the human immune system to fight toxic moieties with higher efficacy and specificity and are expected to have lower side-effects when compared to antibodies of non-human origin. However a large amount of blood samples is required to identify the rarest and most specific antibodies. Mabylon is a biotechnology company that capitalizes on the human body’s own protective capability to generate antibodies against human disease. Mabylon’s unique screening platform allows identification of a needle in the haystack and develop fully human antibodies for diseases with high unmet medical need in the field of allergies and neurodegenerative diseases. Mabylon is currently developing several antibodies including an antibody for TDP-43, a toxic protein associated with diseases progression in ALS and FTD. ALS as a potential initial market could generate €110M in licensing revenue in 2021-2025 and €170M in royalties (5%) from 2026-2030. In addition, platform expansion towards other indications addresses a total neurodegenerative drug market worth €40B by 2022. In the HominAb project, we will investigate our market positioning, the commercial landscape, preclinical development and licensing strategy in order to enable successful commercial maturation of our platform for neurodegenerative diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores